Search Back New search Go to resultsDiseaseMain groupHematologic NeoplasmsSolid TumorsProtocol groupDermatologic OncologyMyeloproliferative neoplasms (MPN) and myelodysplastic neoplasms (MDS)DiseaseMastocytosis, SystemicSubgroupICD10C94.3-C96.2MeSHMastocytosis, SystemicSequenceChemotherapyChemo-substanceMidostaurinChemo-substanceMidostaurinChemo-substanceMidostaurinChemo-substanceMidostaurinNo. Substances1 RadiotherapySupportive therapySupportive substanceDexamethasoneGranisetronSupportive substanceDexamethasoneGranisetronSupportive substanceDexamethasoneGranisetronSupportive substanceDexamethasoneGranisetronNo. Substances2Protocol classificationTherapy classificationcurrent standardIntensityStandard doseTherapy indicationseveral possibleTherapy phaseTherapy intentionpalliativeRisksAnemia Hb below 8g/dlDiarrheaEdemaEmetogenicity (ASCO)FatigueNeutropeniaPyrexiaThrombocytopenia below 50 000/µl only studiesPublicationAuthorGotlib JDiseaseaggr. syst. Mastozytose, Mastozytose mit hämatolog. Neoplasie, Mastzellenleukämie, ECOG 0-3OriginHematology Division, Stanford University School of Medicine–Stanford Cancer Institute, Stanford, CA Protocols in Revision 1 protocol foundProtocols under revision.Midostaurin 100, Aggressive Systemic Mastocytosis (PID1082 V1.1)
